T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy

• Published in: Npj genomic medicine Vol. 8; no. 1; p. 19
• Main Authors: Miyashita, Hirotaka, Kurzrock, Razelle, Bevins, Nicholas J., Thangathurai, Kartheeswaran, Lee, Suzanna, Pabla, Sarabjot, Nesline, Mary, Glenn, Sean T., Conroy, Jeffrey M., DePietro, Paul, Rubin, Eitan, Sicklick, Jason K., Kato, Shumei
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 08.08.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/114/2785; 631/67/580; Apoptosis; Bioinformatics; Biomedical and Life Sciences; Biomedicine; Breast cancer; Cancer; CD137 antigen; CD27 antigen; CD28 antigen; CD40 antigen; CD80 antigen; CD86 antigen; Cytotoxicity; Gene Function; Gene Therapy; Granzyme B; Human Genetics; Immune checkpoint inhibitors; Immunotherapy; Internal Medicine; Lymphocytes T; Microsatellite instability; Mutation; Pancreatic cancer; PD-L1 protein; Serine proteinase; Statistical analysis; Transcriptomics; Tumor necrosis factor; Tumors

Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application of these agents in the clinic is challenging due to immune complexity and heterogeneity. We interrogated transcriptomics of 15 TPMs (CD137, CD27,...